Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Ann...
Deciphera Pharmaceuticals, Inc. (DCPH)
Last deciphera pharmaceuticals, inc. earnings: 3/9 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
deciphera.com/investor-relations
Company Research
Source: Business Wire
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment –– Company Expects to Submit a New Drug Application (NDA) in the Second Quarter of 2024 and Marketing Authorisation Application (MAA) in the Third Quarter of 2024 – WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company’s MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, and have been published in The Lancet.The article titled “Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTIO
Show less
Read more
Impact Snapshot
Event Time:
DCPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCPH alerts
High impacting Deciphera Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
DCPH
News
- Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) [Yahoo! Finance]Yahoo! Finance
- Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)PR Newswire
- Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet [Yahoo! Finance]Yahoo! Finance
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RBAZ Bancorp, Inc. (OTCPK - RBAZ), Squarespace, Inc. (NYSE - SQSP), PlayAGS, Incorporated (NYSE - AGS), Deciphera Pharmaceuticals, Inc. (Nasdaq - DCPH)GlobeNewswire
- SHAREHOLDER ALERT: Halper Sadeh LLC Continues to Investigate SQSP, DPSI, DCPH, HRTPR Newswire
DCPH
Earnings
- 5/10/24 - Beat
DCPH
Sec Filings
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- DCPH's page on the SEC website